In 2025, a wave of states moved to restrict how outside capital can control a medical practice, and the laws landed hardest on the structure private equity has used to roll up physician practices for the last decade. Oregon's Senate Bill 951, signed in June 2025, bans the common arrangement where a management company and the professional medical entity share ownership, and it bars a management company from controlling clinical staffing, scheduling, billing, and payer contracts. California followed with Senate Bill 351 and Assembly Bill 1415, the latter effective at the start of 2026, extending pre-transaction notice requirements to private equity firms and management organizations acquiring healthcare practices. At least a dozen states introduced similar legislation in 2025 alone. The same rules that complicate the leveraged control model also clarify the path for a clean one, which is the part of the story most relevant to an investor deciding which structure to back.

Why the New Laws Target the PE Ophthalmology Structure

The standard private equity physician practice structure relies on a management company that holds significant control over the medical entity through equity-linked agreements and operational authority over staffing, coding, and contracting. Because most states prohibit non-physicians from owning medical practices outright, private equity developed the friendly professional corporation arrangement, where a physician nominally owns the practice but a management company controls the economics and much of the operation through layered contracts. Oregon's law takes direct aim at that arrangement, prohibiting dual ownership between the management company and the medical practice and forbidding the management side from controlling the clinical and business levers it traditionally pulled.

Existing arrangements in Oregon have until the start of 2029 to comply, which means platforms built on the targeted structure now face a deadline to restructure, unwind, or exit the state. The legislative concern driving these bills is consistent across jurisdictions. Lawmakers have grown wary that outside capital has been exercising control over medical decisions that should remain with licensed physicians, and the structures being targeted are precisely the ones built to maximize that control while keeping the physician ownership nominal. The friendly professional corporation, the equity transfer restriction, and the management agreement that reaches into clinical operations are exactly the features the new laws were written to restrict.

How a Compliant Ophthalmology MSO Looks Different

A management services organization that charges a fixed, fair-market-value fee for genuine administrative services, holds no equity transfer rights over the medical practice, and leaves all clinical and business decision-making with the physician owners is built on the opposite principle from the structures these laws target. The clinical entity stays physician-owned and physician-controlled in substance rather than only in name. The management company supports operations under a clearly bounded agreement and does not reach into staffing, coding, or payer decisions. It provides administrative services and charges a fair price for them, and it stops there.

As state after state tightens the rules, this clean structure does not need to be retrofitted, because it was never built on the control mechanisms the new laws prohibit. A platform that already operates this way carries no compliance deadline, no restructuring cost, and no regulatory overhang in the states tightening their rules. The distinction matters because the two models look superficially similar to an outsider. Both involve a management company and a physician practice. The difference lies in who actually controls clinical and business decisions and in whether the management company holds equity-linked control over the practice, and that difference is exactly what the new statutes have made legally decisive.

What the Regulatory Shift Means for Ophthalmology Capital

For a capital allocator, the trend matters because it changes the durability of the underlying structure being acquired. A platform built on the control-heavy model now faces compliance deadlines, potential restructuring costs, and regulatory uncertainty in a growing number of states, all of which represent risk to the value of the investment. A platform built on a clean, fixed-fee, physician-controlled model gains a structural advantage that widens with each new statute, because the regulatory direction keeps validating the model it already uses.

The laws are still being written, the trend is still spreading across states, and the direction has been consistent. Capital that values durable structure should read the regulatory map as a reason the compliant ophthalmology model is becoming more defensible rather than less, exactly as the rules tighten around the leveraged alternatives. The regulatory wind that complicates the control-heavy model leaves the compliant model untouched, and over time that distinction compounds into a meaningful difference in risk and durability.

What the Ophthalmology Diligence Checklist Now Has to Cover

An allocator underwriting a healthcare platform in 2026 is underwriting its regulatory resilience as much as its cash flow, and on that measure the clean structure is the one moving in the right direction. The diligence implication is concrete. An allocator evaluating any physician-services platform should ask a short list of structural questions before looking at a single financial projection. Does the management company hold any equity-linked control over the medical practice. Does it control clinical staffing, coding, billing, or payer contracting. Would the structure survive an Oregon-style statute without restructuring. A platform that answers those questions cleanly carries a durability that does not show up in a multiple or a growth rate, but that protects the entire investment as the regulatory environment continues to tighten.

The reason this matters more now than it did even two years ago is the direction of travel. For most of the last decade, the corporate-practice-of-medicine doctrine existed on the books in many states but was loosely enforced, which let the control-heavy structure proliferate with little consequence. The 2025 wave of legislation signals that the loose-enforcement era is ending, and the new statutes attach real deadlines and real teeth to the doctrine. A platform that was structured for the loose-enforcement world now faces a tightening one, and the cost of that mismatch lands on whoever owns the platform when a statute takes effect. An allocator buying into such a platform is buying that latent liability, whether or not it appears in the current financials.

A platform that cannot answer the structural questions cleanly carries a latent liability that may not appear in the financials today but becomes a restructuring cost or a forced exit tomorrow. The regulatory shift has turned what used to be a back-office structuring detail into a front-line determinant of which platforms are safe to own for the long term. For permanent capital in particular, which intends to hold through many legislative cycles rather than exit before the next one, structural resilience is not a compliance footnote. It is one of the central questions that determines whether the asset can actually be held for the decades the thesis requires.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com